TheR1441C-LRRK2mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner
Author:
Wallings Rebecca L.ORCID, McFarland Karen, Staley Hannah A., Neighbarger Noelle, Schaake Susen, Brüggemann Norbert, Zittel Simone, Usnich Tatiana, Klein Christine, Sammler Esther MORCID, Tansey Malú Gámez
Abstract
AbstractConsidering age is the greatest risk factor for many neurodegenerative diseases, aging, in particular aging of the immune system, is the most underappreciated and understudied contributing factor in the neurodegeneration field. Genetic variation around theLRRK2gene affects risk of both familial and sporadic Parkinson’s disease (PD). The leucine-rich repeat kinase 2 (LRRK2) protein has been implicated in peripheral immune signaling, however, the effects of an aging immune system on LRRK2 function have been neglected to be considered. We demonstrate here that theR1441Cmutation induces a hyper- responsive phenotype in macrophages from young female mice, characterized by increased effector functions, including stimulation-dependent antigen presentation, cytokine release, phagocytosis, and lysosomal function. This is followed by age-acquired immune cell exhaustion in a Lrrk2-kinase-dependent manner. Immune-exhausted macrophages exhibit suppressed antigen presentation and hypophagocytosis, which is also demonstrated in myeloid cells fromR1441CandY1699C-PD patients. Our novel findings thatLRRK2mutations confer immunological advantage at a young age but may predispose the carrier to age-acquired immune exhaustion have significant implications for LRRK2 biology and therapeutic development. Indeed, LRRK2 has become an appealing target in PD, but our findings suggest that more research is required to understand the cell-type specific consequences and optimal timing of LRRK2- targeting therapeutics.One Sentence SummaryTheR1441C-LRRK2mutation causes an age-acquired immune cell exhaustion in macrophages in sex-dependent manner
Publisher
Cold Spring Harbor Laboratory
Reference84 articles.
1. Von Campenhausen, S. , B. Bornschein , R. Wick , K. Bötzel , C. Sampaio , W. Poewe , W. Oertel , U. Siebert , K. Berger , and R. Dodel , Prevalence and incidence of Parkinson’s disease in Europe. 15(4): p. 473-490 (2005). 2. Marras, C. , J.C. Beck , J.H. Bower , E. Roberts , B. Ritz , G.W. Ross , R.D. Abbott , R. Savica , S.K. Van Den Eeden , A.W. Willis , C.M. Tanner , and P.G. Parkinson’s Foundation , Prevalence of Parkinson’s disease across North America. NPJ Parkinsons Dis. 4: p. 21 (2018). 3. Yang, W. , J.L. Hamilton , C. Kopil , J.C. Beck , C.M. Tanner , R.L. Albin , E. Ray Dorsey , N. Dahodwala , I. Cintina , P. Hogan , and T. Thompson , Current and projected future economic burden of Parkinson’s disease in the U.S. npj Parkinson’s Disease. 6(1) (2020). 4. Bloem, B.R. , M.S. Okun , and C. Klein , Parkinson’s disease. Lancet. 397(10291): p. 2284-2303 (2021). 5. Tansey, M.G. , Wallings, R. L. , Houser, M. C. , Herrick, M. K. , Keating, C. E. & Joers, V ., The contributions of inflammation and immune dysfunction to Parkinson disease. Nature Reviews Immunology. (2022).
|
|